Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza

GAITHERSBURG, Md., Sept. 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials